It has been shown that IL-40 levels in RA patients are not affected by TNF inhibitor therapy such as adalimumab, whereas IL-40 levels are decreased by B cell depletion therapy such as rituximab [8]. This evidence concerns the gene C17orf99 and rheumatoid arthritis.